IMMU-67. PERSONALIZED TUMOR MRNA LOADED LIPID NANOPARTICLES PRIME THE SYSTEMIC AND INTRATUMORAL GBM MILIEU FOR RESPONSE TO IMMUNOTHERAPY

BACKGROUND: In a randomized phase III study for recurrent glioblastoma (GBM), combination therapy with immune checkpoint inhibitors (ICIs) nivolumab and ipilimumab failed to improve overall survival. Since ICIs appear to be dependent on host-myeloid (and not tumor-cell) expression of PD-L1 (Tang et...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Sayour, Elias, Grippin, Adam, De Leon, Gabriel, Stover, Brian, Huang, Jianping, Deleyrolle, Loic, Sahay, Bikash, Carrera-Justiz, Sheila, Mendez-Gomez, Hector, Mitchell, Duane
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2018
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216690/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.570
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados